13-Decyl Berberine Derivative Is a Novel Mitochondria-Targeted Antioxidant and a Potent Inhibitor of Ferroptosis
He Huan, Alisa A Panteleeva, Ruben A Simonyan, Armine V Avetisyan, Natalia V Sumbatyan, Konstantin G Lyamzaev, Boris V Chernyak, M-Saadeh Suleiman · 2025
Read 13-Decyl Berberine Derivative Is a Novel Mitochondria-Targeted Antioxidant and a Potent Inhibitor of Ferroptosis by He Huan, Alisa A Panteleeva, Ruben A Simonyan, Armine V Avetisyan, Natalia V Sumbatyan, Konstantin G Lyamzaev, Boris V Chernyak, M-Saadeh Suleiman (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12732116.txt.
Description
He Huan and co-authors report a new form of berberine that guards the cell's power plants in 2025. Berberine is a plant alkaloid long used in traditional medicine, but its shield against oxidation is weak. Ferroptosis is a form of cell death driven by lipid peroxidation. That death feeds ills tied to too much oxidative stress in the body.
The team gave the drug a tail of ten carbons, and that tail sent it straight into mitochondria. Once there, it cut lipid peroxidation and the flow of reactive oxygen at far lower doses than plain berberine. The tests used heart cells and human fibroblasts, and the new form slowed the buildup of age pigment. A drug aimed at the spot where harm piles up hits much harder. That is why this form works so well at such low doses.
Catalog record
| CREATOR | He Huan, Alisa A Panteleeva, Ruben A Simonyan, Armine V Avetisyan, Natalia V Sumbatyan, Konstantin G Lyamzaev, Boris V Chernyak, M-Saadeh Suleiman |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |